產品資訊 - Meningococcal Polysaccharide Vaccine Groups->aspalthic products

登入

加入會員

求助

Changchun Changsheng Life Sciences Ltd.

	Recommended Results

Meningococcal Polysaccharide Vaccine Groups

產品分類 :

化學->化學用品->aspalthic products

Meningococcal Polysaccharide Vaccine Groups

產品規格

Model No:	0.5ml/vial

Country	CN
Minimum Order	5000
Payment Term	L/C,T/T

產品描述

ACYW135 Meningococcal Polysaccharide Vaccine


 
[Eligibles] 
Adults and children over two years of age. 
[Function and use] 
The vaccine is indicated for active immunization against invasive meningococcal disease caused by epidemic Neisseria meningitidis serogroups A,C,Y,W135. 
[Description] 
The vaccine is a preparation of preparation polysaccharide antigens extracted from the culture of Neisseria meningitidis group ACYW135 respectively and Iyophilized after addition of an appropriate stabilizer. The final product looks like a white crisp cake. It shall dissolve in the accompanying Phosphate buffered saline (PBS) immediately, and turn into a clear liquid after reconstitution. 
Active constituent: Neisseria meningitidis group ACYW135 capsular polysaccharides. 
Subsidiary materials: All the components of subsidiary materials approved shall be listed. 
Vaccine diluent: Sterile, pyrogen-free PBS. 
[Specifications] 
0.5 ml of reconstituted vaccine per container. 0.5 ml per single human dose, containing  200μg of meningococcal polysaccharide (50μg of each polysaccharide of group A,C,Y,W135). 
[Feature] 
Fill a gap in our country for the first time by developing 4-valent vaccine . 
Improve traditional purification technology to eliminate nucleic acid and protein. 
Improve WHO specifications and high harvest rate. Develop new type of stabilizer. Improve national quality standards. 
[Advantages] 
(1)Apply modern biotechnology to purification involved in manufacture and best technology process for culture preparation; 
(2)Apply automatic fermentation system for bacterial culture to whole production process; 
(3)High purity vaccine with high quality indexes; 
(4)High-level immunogenicity, high GMT level of conversion rate of antibody PT, FHA, T and D in serum, providing ideal protection and prevention; 
(5)One dose for immunization to prevent infection of four meningococcal; 
(6)Lyophilized dosage form for quality guarantee; 
(7)Large annual production capability to meet the demands of different groups for the prevention of meningococcal disease. 
<div>
 
</div>
 
1.Group ACYW135                              
2.Group A+C                                       
3.prevent epidemic cerebrospinal meningitis                                                   


4.purified capsular polysaccharide antigens  
<img src="http://i.bosscdn.com/product/18/f2/13/d46381b9bd8edf65b150508726.png@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="-ACYW135" alt="-ACYW135" /> 
 



 
ccls-vaccine.com

其他類似產品